Plasma Fractionation Market Business Insights

As reported by SNS Insider, the global Plasma Fractionation Market was valued at USD 33.47 billion in 2023 and is projected to reach USD 63.82 billion by 2031, growing at a compound annual growth rate (CAGR) of 8.4% over the forecast period from 2024 to 2031.

Market Overview

Plasma fractionation is a process used to separate and purify various components of human plasma, including clotting factors, immunoglobulins, and albumin. These components are essential for treating a range of medical conditions, such as bleeding disorders, immune deficiencies, and liver diseases. The market for plasma fractionation is expanding due to the rising prevalence of hemophilia, increasing demand for immunoglobulins, and advancements in fractionation technologies that improve product yield and safety.

Get Free Sample Copy of Report: https://www.snsinsider.com/sample-request/2992 

Key Players

• CSL Limited
• Grifols S.A.
• Takeda Pharmaceutical Company Limited
• Octapharma AG
• Shire (now part of Takeda)
• BioLife Plasma Services
• Kedrion Biopharma
• LFB Group
• Shanghai Raas Blood Products Co., Ltd.
• Hualan Biological Engineering Inc.

KEY MARKET SEGMENTATION

By Product Type

• Immunoglobulins
• Clotting Factors
• Albumin
• Others

By Application

• Hemophilia
• Immune Deficiencies
• Liver Diseases
• Other Therapeutic Areas

By End Users

• Hospitals
• Blood Banks
• Research Institutes
• Others

Market Dynamics

• Increasing Prevalence of Hemophilia: The rising number of hemophilia cases globally is driving the demand for plasma-derived clotting factors. Advances in treatment options are contributing to the growth of the plasma fractionation market.
• Growing Demand for Immunoglobulins: Immunoglobulins are used to treat a variety of immune disorders and are in high demand due to their critical role in managing autoimmune diseases and infections.
• Technological Advancements: Innovations in plasma fractionation technology, such as improved separation techniques and enhanced product safety measures, are boosting market growth. These advancements lead to higher yields and better patient outcomes.
• Expansion of Plasma Collection Networks: The growth of plasma collection centers and increased public awareness about plasma donation are supporting market expansion and ensuring a steady supply of plasma for fractionation.

Regional Insights

• North America: Leads the market due to the presence of major pharmaceutical companies, advanced healthcare infrastructure, and a high prevalence of plasma-derived therapies.
• Europe: Shows substantial growth potential, driven by increasing investments in healthcare and rising demand for plasma-derived products.
• Asia-Pacific: Expected to experience rapid growth due to expanding healthcare infrastructure, a growing patient population, and increasing awareness of plasma fractionation benefits.

Key Players

• CSL Limited
• Grifols S.A.
• Takeda Pharmaceutical Company Limited
• Octapharma AG
• Shire (now part of Takeda)

Future Outlook

The Plasma Fractionation Market is poised for significant growth, driven by the increasing prevalence of blood disorders, rising demand for plasma-derived therapies, and technological advancements in fractionation processes. Continued investment in research and development is expected to further enhance market expansion and improve treatment options.

Table of Contents

1. Introduction
2. Research Methodology
3. Market Dynamics
4. Impact Analysis
5. Value Chain Analysis
6. Porter’s 5 forces model
7. PEST Analysis
8. Global Human Insulin Market Segmentation, By Product
9. Plasma Fractionation Market Segmentation, By Application
10. Plasma Fractionation Market Segmentation By End User
11. Regional Analysis
12. Company profile
13. Competitive Landscape
14. Used Cases and Best Practices
15. Conclusion

Related Reports

Compression Therapy Market Challenges

Multiple Myeloma Market Challenges

Foley Catheter Market Challenges

Diet Pills Market Challenges

Dentures Market Challenges

Dialysis Market Challenges

Contact Us:

Akash Anand – Head of Business Development & Strategy
info@snsinsider.com
Phone: +1-415-230-0044 (US) | +91-7798602273 (IND)
Website: https://www.snsinsider.com/